DNAJC5 and malaria: Developed through a decades-long partnership between GlaxoSmithKline (GSK), the University of Oxford, PATH Malaria Vaccine Initiative (MVI), and African research institutions, both vaccines represent innovative breakthroughs by inducing immune responses against the Plasmodium falciparum circumsporozoite protein (CSP) to prevent sporozoites from infecting the liver.